{
  "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed",
  "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 52,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 40,
  "notes": "Includes two distinct data cut-off dates for different parts of the safety summary.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/18",
  "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed",
  "deckJsonHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed.json",
  "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.916,
        "x": 0.053,
        "y": 0.225
      },
      "kind": "paragraph",
      "text": "At the final DFS analysis (data cut-off: 11 April 2022), all patients had completed or discontinued study treatment; the safety profile of adjuvant Tagrisso with extended follow-up1,2 was consistent with the ADAURA primary analysis3",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6904f2b7-0fed-44ac-9461-a085d628c762",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.916,
        "x": 0.053,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "At the time of the current data cut-off (27 January 2023), one additional serious AE (COVID-19 pneumonia) had been reported, which occurred >28 days after treatment discontinuation; the investigator determined that this was not treatment-related and the patient made a full recovery",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2b9ef17-da9a-4c80-85ce-ebc25a6669a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.89,
        "x": 0.038,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "*Data cut-off: April 11, 2022. Patients with multiple events in the same category counted only once in that category, Patients with events in more than one category counted once in each of those categories. Includes AEs with an onset date on or after the date of first dose and up to and including 28 days following the discontinuation of study treatment and before starting subsequent cancer therapy. †As assessed by the investigator. 1. Herbst et al. J Clin Oncol 2023;41:1830–1840; 2. John et al. J Thorac Oncol 2023; accepted and under revision; 3. Wu et al. N Engl J Med 2020;383:1711–1723. DFS = disease-free survival; AE = adverse event; COVID-19 = coronavirus disease 2019.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e63c1b4-e359-4841-bbb4-f201ea52ff56",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.42,
        "w": 0.87,
        "x": 0.065,
        "y": 0.318
      },
      "kind": "table",
      "text": "AE, any cause*, n (%) | Tagrisso (n=337) | Placebo (n=343) | Any AE | 330 (98) | 309 (90) | Any AE Grade ≥3 | 79 (23) | 48 (14) | Any AE leading to death | 1 (<1) | 2 (1) | Any serious AE | 68 (20) | 47 (14) | Any AE leading to discontinuation | 43 (13) | 9 (3) | Any AE leading to dose reduction | 42 (12) | 3 (1) | Any AE leading to dose interruption | 91 (27) | 43 (13) | AE, possibly causally related*+, n (%) | Any AE | 308 (91) | 199 (58) | Any AE Grade ≥3 | 36 (11) | 7 (2) | Any AE leading to death | 0 | 0 | Any serious AE | 10 (3) | 2 (1)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0857d81-b3eb-4686-9d95-73ece8697119",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.29,
        "x": 0.034,
        "y": 0.065
      },
      "kind": "title",
      "text": "Safety summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6df2c58a-1252-4677-9cc4-b518b069d7cf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 15,
      "beatId": "ba7e7aa9-525b-4e2a-a4f1-214ecf8f098d",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck presents data and results from various trials, showcasing the company's progress in oncology",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 15,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "b41eaf1b-437d-4b91-9988-0e6fb0f284a8",
      "evidence": "The deck presents data and results from various trials, showcasing the company's progress in oncology",
      "position": 1,
      "objective": "What are the benefits of AstraZeneca's pipeline?",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}